Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide

Merck's efinopegdutide has received FDA Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH), and Merck has released Phase IIa study results comparing efinopegdutide to Novo Nordisk's semaglutide. The new NAFLD data will be presented at the upcoming European Association for the Study of the Liver annual congress, and Merck plans to use both this data and the Fast Trac..